Encouraged by plenty of achievements in antitumor immunotherapy, we evaluated the correlations of our glycolytic risk model and the immune checkpoint molecules PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIM-3, TIGIT, B7-H3, B7-H4, and CD47 in DLBCL. The gene discussed is VTCN1; the disease is diffuse large B-cell lymphoma.